List view / Grid view
Professor Trevor Jones, CBE, FMedSci is the new chairman of EMCA, a body that seeks to advocate for evidence-based policy and improving supply and manufacture of quality medicinal cannabis.
Epidyolex, which contains cannabidiol, can now be prescribed by doctors to epilepsy patients in the UK through the NHS.
Dr Mohamedali discusses Canada's stance on medical cannabis and breaks down some misconceptions surrounding cannabinoids, as well as exploring the future for the pharmaceutical ingredient.
Cannabinoids are of growing interest in the pharmaceutical industry. Mark Tucker explains how this class of compounds is viewed across the world and why regulations surrounding them hinder their progress, yet remain necessary.
Dr Platt describes how medical cannabis can be used to treat conditions such as pain, his area of expertise. He also explains how perception has influenced the acceptance of cannabinoids.
Dr Sodergren explores the uses of medical cannabis, describing its applications. He also discusses the future of cannabinoid research in the short- and long-term.
A medicinal CBD oil has been approved for importation, prescription and supply under the Medical Cannabis Access Programme (MCAP) in Ireland.
The global medical marijuana market will show impressive growth, a new report has said, but this could be hindered due to some doctors being reluctant to prescribe these products.
Dr Englund discusses his research into medical cannabis, highlighting a range of its potential uses. He also explores some of the challenges that can be faced in clinical trials when investigating cannabinoids.
Following guidance from the drugs advisory body NICE, two cannabis-based medications have been approved for treatment by the NHS in England.
Cannabinoids, their potential therapeutic uses and the research needed for medical cannabis were the topics of discussion at the ‘Medical cannabis: what UK doctors need to know’ event held last week.
A business selling unapproved products containing CBD has been sent a warning letter from the FDA and FTC for making unsubstantiated claims about their therapeutic properties.
A pioneering clinical study will assess the safety, tolerability and effectiveness of CBD in people with Parkinson's-related psychosis.
The CQC decision marks the first time the agency has accepted a clinic to prescribe patients with medical cannabis in the UK.
An event was held last week, exploring the manufacturing and potential of cannabinoids within the pharmaceutical industry.
